Why the study?
Does oral anticoagulation with edoxaban or apixaban reduce the risk of stroke in patients with device-detected atrial fibrillation?
Does oral anticoagulation with edoxaban or apixaban reduce the risk of stroke in patients with device-detected atrial fibrillation?
In patients with device-detected atrial fibrillation, oral anticoagulation with edoxaban or apixaban effectively reduces stroke risk at the cost of increased major bleeding.
Guides individualized anticoagulation decisions in device-detected AF by balancing stroke prevention against bleeding; extends RCT evidence via meta-analysis.
The results of the NOAH-AFNET 6 and ARTESiA trials are consistent with each other. Meta-analysis of these 2 large randomized trials provides high-quality evidence that oral anticoagulation with edoxaban or apixaban reduces the risk of stroke in patients with device-detected atrial fibrillation and increases the risk of major bleeding.
No takes yet. Share an insight, caveat, or question.
McIntyre et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: